FIRST-IN-HUMAN PHASE 1/2 STUDY OF UBAMATAMAB, A MUC16XCD3 BISPECIFIC ANTIBODY, ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER

Category Primary study
JournalInternational journal of gynecological cancer
Year 2023
This article has no abstract
Epistemonikos ID: 764ad07a1b3f8747fa53256394d4b20b71089bc3
First added on: Feb 29, 2024